Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

ATLANTA, Oct. 14, 2022 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company’s management team will be attending the 78^th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress to be held in Anaheim, California from October 22-26, 2022.

Members of the management team will be showcasing its technologies, including FemaSeed^® and FemVue^®, at its booth #1011.

About Femasys
Femasys Inc. is a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc^® permanent birth control and FemaSeed^® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue^®, and FemCerv^®, an endocervical tissue sampler are currently being marketed in the United States. Femasys is also advancing FemCath^™, an intrauterine catheter for selective evaluation of the fallopian tubes intended to be marketed alongside its other women-specific medical products in the physician’s office setting. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com 

Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com 

Femasys Inc.
Investor Contact:
IR@femasys.com 

Media Contact:
Media@femasys.com